The resulting OPBP-1@TMC formulation demonstrated an enhanced oral bioavailability and significant tumor suppression in colorectal CT26 mouse models through PD-1/PD-L1 pathway inhibition [89] (Figure 3). The gene discussed is CD274; the disease is neoplasm.